Martin Tolstrup

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).

Entecavir therapy induces de novo HIV reverse-transcriptase M184V mutation in an antiretroviral therapy-naive patient.

Population-based study of diagnostic assays for Borrelia infection: comparison of purified flagella antigen assay (Ideia, Dako Cytomation) and recombinant antigen assay (Liaison, DiaSorin).

Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.

Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.

Endotoxemia is associated with altered innate and adaptive immune responses in untreated HIV-1 infected individuals.

Induction of humoral and cellular immune responses against the HIV-1 envelope protein using γ-retroviral virus-like particles.

Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.

Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice.

Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.

Construction of a gammaretrovirus with a novel tropism and wild-type replication kinetics capable of using human APJ as entry receptor.

TLR9-adjuvanted pneumococcal conjugate vaccine induces antibody-independent memory responses in HIV-infected adults.

The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults.

Antiviral and immunological effects of tenofovir microbicide in vaginal herpes simplex virus 2 infection.

Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation.

Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials.

Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients.

Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models.

Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.

Editorial commentary: Reversing latency in HIV-infected patients.

T cells detect intracellular DNA but fail to induce type I IFN responses: implications for restriction of HIV replication.

Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.

Polymers fight HIV: potent (pro)drugs identified through parallel automated synthesis.

Highly active macromolecular prodrugs inhibit expression of the hepatitis C virus genome in the host cells.

Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives.

Disulfide reshuffling triggers the release of a thiol-free anti-HIV agent to make up fast-acting, potent macromolecular prodrugs.

The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau.

Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.

Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system.

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy.

Reversal of Latency as Part of a Cure for HIV-1.

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients.

Polyanionic Macromolecular Prodrugs of Ribavirin: Antiviral Agents with a Broad Spectrum of Activity.

ART influences HIV persistence in the female reproductive tract and cervicovaginal secretions.

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.

A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.

Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.

The potential role for romidepsin as a component in early HIV-1 curative efforts.

New insights on the phenotype of HIV reservoirs.

Triple Activity of Lamivudine Releasing Sulfonated Polymers against HIV-1.

International AIDS Society global scientific strategy: towards an HIV cure 2016.

Immune checkpoints and the HIV-1 reservoir: proceed with caution.

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.

Broad activation of latent HIV-1 in vivo.

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.

Macromolecular Prodrugs of Ribavirin: Structure-Function Correlation as Inhibitors of Influenza Infectivity.

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.

Beyond antiretroviral therapy: early interventions to control HIV-1 infection.

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Macromolecular prodrugs of ribavirin: towards a treatment for co-infection with HIV and HCV.

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Macromolecular Antiviral Agents against Zika, Ebola, SARS, and Other Pathogenic Viruses.

Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.

Macromolecular prodrugs of ribavirin: Polymer backbone defines blood safety, drug release, and efficacy of anti-inflammatory effects.

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Lipopolysaccharide-Induced Inflammatory Responses.

Levels of regulatory B cells do not predict serological responses to hepatitis B vaccine.

Multiple Homozygous Variants in the STING-Encoding Gene in HIV Long-Term Nonprogressors.

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.

HIV anti-latency treatment mediated by macromolecular prodrugs of histone deacetylase inhibitor, panobinostat.

Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin.

Whole Exome Sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules.

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.

Non-covalent hitchhiking on endogenous carriers as a protraction mechanism for antiviral macromolecular prodrugs.

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.

cAIMP administration in humanized mice induces a chimerization-level-dependent STING response.

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

Nucleic Acids as a Nature-Inspired Scaffold for Macromolecular Prodrugs of Nucleoside Analogues.

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease.

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency without T cell activation.